Alumis (ALMS) and Acelyrin (SLRN) said Monday that they agreed on an amended merger deal that reflects an increased share consideration for each Acelyrin share.

Under the amended agreement, Acelyrin shareholders will receive 0.4814 of an Alumis common share for each Acelyrin common share held, according to the statement. The companies said this represents a "meaningful increase" over the initial agreement.

The new deal terms will give Alumis shareholders a 52% stake in the merged company, while Acelyrin shareholders will own the remaining 48% stake, according to the companies.

Shareholders who own about 62% of Alumis's voting stock and Acelyrin shareholders who own about a 24% interest in the company have signed voting agreements to support the transaction, according to the statement. The companies are set to hold special meetings in May to seek shareholder approval for the merger.